Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy

Douglas Daoudlarian,Amandine Segot,Sofiya Latifyan,Robin Bartolini,Victor Joo,Nuria Mederos,Hasna Bouchaab,Rita Demicheli,Karim Abdelhamid,Nabila Ferahta,Jacqueline Doms,Grégoire Stalder,Alessandra Noto,Lucrezia Mencarelli,Valérie Mosimann,Dominik Berthold,Athina Stravodimou,Claudio Sartori,Keyvan Shabafrouz,John A Thompson,Yinghong Wang,Solange Peters,Giuseppe Pantaleo,Michel Obeid

DOI: https://doi.org/10.1101/2024.07.12.24310333

2024-07-12

Abstract:Immune-related cytokine release syndrome (irCRS) frequently occurs during immune checkpoint inhibitor (ICI) therapy. In the present study, we have attempted to identify biomarkers in oncology patients experiencing irCRS-like symptoms (n=35), including 9 patients with hemophagocytic lymphohistiocytosis (irHLH)-like manifestations (8 classified as Grade (G) 4 irCRS and 1 as G3 irCRS) and 8 with sepsis, differentiating between irCRS, irHLH and sepsis. Patients grouped in three clusters based on distinct cytokine profiles and survival outcomes. We identified 24 biomarkers that significantly discriminated between irHLH and irCRS G3 (P < 0.0455 to < 0.0027). Notably, HGF and ferritin demonstrated superior predictive values over the traditional HScore, with a positive predictive value (PPV) and negative predictive value (NPV) of 100%. Furthermore, CXCL9 not only distinguished between irHLH and irCRS G3, but was also a predictor of treatment intensification with tocilizumab (TCZ) with a PPV of 90% and a NPV of 100%. Other parameters, such as leukocyte count, neutrophils, ferritin, IL-6, IL-7, EGF, fibrinogen, and GM-CSF, were effective in discriminating sepsis from high-grade irCRS with a PPV of 75-80% and an NPV of 100%. In comparison to sepsis, the frequencies of CXCR5+ or CCR4+ CD8 memory, CD38+ ITM monocytes, and CD62L+ neutrophils were observed to be higher in high-Grade irCRS. Of note, TCZ treatment led to complete resolution of clinical symptoms in 12 patients with high-grade irCRS refractory to corticosteroids (CS). These findings demonstrate the power of unique immunologic biomarkers in determining the severity of irCRS, in predicting survival, and distinguishing between high-grade irCRS, irHLH and sepsis. Therefore, these distinct unique signatures are instrumental for the optimal development of personalized clinical and therapeutic management in patients experiencing irCRS patient.

Oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify unique immune characteristics in the clinical management of immune - related cytokine release syndrome (irCRS) during the treatment with immune checkpoint inhibitors (ICI). Specifically, the study aims to:

1. **Identify biomarkers**: Determine specific biomarkers that can distinguish different clinical manifestations of irCRS (including irHLH and sepsis) to improve the accuracy of diagnosis.
2. **Evaluate clinical severity**: Evaluate the clinical severity of irCRS through these biomarkers and predict the survival rate of patients.
3. **Guide treatment decisions**: Identify biomarkers that can predict the need for intensive treatment (such as the use of tocilizumab TCZ), thereby optimizing the treatment plan.

### Main research content

- **Background**: Immune checkpoint inhibitors (ICIs) have shown significant efficacy in the treatment of various cancers, but they are also accompanied by a series of immune - related adverse events (irAEs), among which immune - related cytokine release syndrome (irCRS) is a particularly concerning issue. irCRS may lead to severe systemic inflammatory reactions and even endanger lives.
- **Research objective**: By analyzing a set of 115 biomarkers (including 50 cytokines, chemokines and growth factors, and 44 cell markers), identify specific biomarkers that can distinguish different clinical manifestations of irCRS (including irHLH and sepsis), and evaluate their value in predicting clinical severity and treatment decisions.
- **Methods**:
- **Patient cohort**: From 2020 to the end of 2023, a total of 35 patients who received ICI treatment and developed systemic inflammatory response syndrome (SIRS) were included.
- **Biomarker analysis**: A comprehensive cytokine and biological marker analysis was performed on the serum samples of these patients.
- **Cluster analysis**: Using the K - means clustering algorithm, combined with multiple biomarkers, patients were divided into different survival groups.
- **Results**:
- **Biomarker identification**: 24 biomarkers that significantly distinguish irHLH and irCRS G3 were found, among which HGF and ferritin had the highest predictive value, with 100% positive predictive value (PPV) and negative predictive value (NPV).
- **Survival analysis**: Through cluster analysis, patients were divided into three different survival groups, and the survival rates of each group were significantly different.
- **Treatment prediction**: CXCL9 can not only distinguish irHLH and irCRS G3, but also predict patients who need to be treated with tocilizumab (TCZ), with a PPV of 90% and an NPV of 100%.

### Conclusion

This study provides important tools for the clinical management and treatment decision - making of irCRS by identifying specific biomarkers. These biomarkers not only help to diagnose and evaluate the severity of irCRS more accurately, but also predict which patients need more aggressive treatment, thereby improving the prognosis of patients.